Advanced Therapies Put New Pressure on Canadian CDMO Selection
A pharmaceutical company developing an advanced therapy may reach a difficult decision before manufacturing begins. The scientific platform can be promising, yet the available CDMO options may not have the facilities, technical experience or development processes needed to move the program forward. For sponsors working with complex modalities, choosing a manufacturing partner has become part of the development strategy rather than a later procurement decision.
The issue is especially relevant when a therapy requires production methods that differ from conventional small-molecule manufacturing. A CDMO may have broad pharmaceutical experience but still lack the specific technical background needed for a more specialized program. Sponsors, therefore, have to look beyond general manufacturing capacity when assessing potential partners.
That assessment can affect the development timeline. A mismatch between the therapy and the CDMO's capabilities may create delays when processes need to be adapted or transferred. The problem may appear after the relationship has already been established, when changing partners becomes expensive and disruptive.
Canadian CDMOs are therefore operating in a market where technical fit carries greater weight in outsourcing decisions. A sponsor evaluating a potential partner may need to examine how the CDMO approaches development work, process transfer and manufacturing scale. The question is less about whether a facility can produce pharmaceutical material in general. It is whether the facility can handle the particular demands of the therapy under development.
Advanced therapies also change the way sponsors think about outsourcing risk. A company may have limited internal manufacturing infrastructure and depend heavily on an external partner. That can make the CDMO's development experience a central factor in the program, particularly when the sponsor is moving through unfamiliar manufacturing requirements.
The decision can become more complicated when a program evolves. A process that works at an early development stage may need further adjustment as production requirements change. Sponsors may then find that the most suitable partner is the one capable of supporting the program beyond its immediate manufacturing need.
For pharmaceutical companies, the practical question is how early to test that fit. Waiting until a program reaches a later stage can limit the available choices. Early evaluation may provide a clearer view of whether a CDMO can support the therapy as its manufacturing requirements become more demanding.
The Canadian CDMO market may see more outsourcing decisions shaped by this issue. For advanced therapies and other complex modalities, the manufacturing partner is becoming part of the development process. Sponsors may still compare cost and capacity, but the partner's technical fit may matter even more.
